CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.
from The Medical News http://ift.tt/1wiw5k4
from The Medical News http://ift.tt/1wiw5k4
No comments:
Post a Comment